» Articles » PMID: 32805678

Progressive Brain Atrophy and Clinical Evolution in Parkinson's Disease

Overview
Journal Neuroimage Clin
Publisher Elsevier
Specialties Neurology
Radiology
Date 2020 Aug 18
PMID 32805678
Citations 29
Authors
Affiliations
Soon will be listed here.
Abstract

Clinical manifestations and evolution are very heterogeneous among individuals with Parkinson's disease (PD). The aims of this study were to investigate the pattern of progressive brain atrophy in PD according to disease stage and to elucidate to what extent cortical thinning and subcortical atrophy are related to clinical motor and non-motor evolution. 154 patients at different PD stages were assessed over time using motor, non-motor and structural MRI evaluations for a maximum of 4 years. Cluster analysis defined clinical subtypes. Cortical thinning and subcortical atrophy were assessed at baseline in patients relative to 60 healthy controls. Longitudinal trends of brain atrophy progression were compared between PD clusters. The contribution of brain atrophy in predicting motor, non-motor, cognitive and mood deterioration was explored. Two main PD clusters were defined: mild (N = 87) and moderate-to-severe (N = 67). Two mild subtypes were further identified: mild motor-predominant (N = 43) and mild-diffuse (N = 44), with the latter group being older and having more severe non-motor and cognitive symptoms. The initial pattern of brain atrophy was more severe in patients with moderate-to-severe PD. Over time, mild-diffuse PD patients had the greatest brain atrophy accumulation in the cortex and the left hippocampus, while less distributed atrophy progression was observed in moderate-to-severe and mild motor-predominant patients. Baseline and 1-year cortical thinning was associated with long-term progression of motor, cognitive, non-motor and mood symptoms. Cortical and subcortical atrophy is accelerated early after the onset of PD and becomes prominent in later stages of disease according to the development of cognitive, non-motor and mood dysfunctions. Structural MRI may be useful for monitoring and predicting disease progression in PD.

Citing Articles

An Unusual Presentation of Peri-Lead Edema Following Deep Brain Stimulation for Parkinson's Disease: A Case Report and Review of the Literature.

Witzig V, Pjontek R, Hollig A, Schiefer J, Wiesmann M, Clusmann H Clin Case Rep. 2025; 13(3):e70221.

PMID: 40062311 PMC: 11885058. DOI: 10.1002/ccr3.70221.


Item-Level Analysis of Category Fluency Test Performance: A Systematic Review and Meta-Analysis of Studies of Normal and Neurologically Abnormal Ageing.

De Marco M, Wright L, Makovac E Neuropsychol Rev. 2025; .

PMID: 39841364 DOI: 10.1007/s11065-024-09657-z.


Changes in Action Tremor in Parkinson's Disease over Time: Clinical and Neuroimaging Correlates.

van den Berg K, Johansson M, Dirkx M, Bloem B, Helmich R Mov Disord. 2024; 40(2):292-304.

PMID: 39679819 PMC: 11832800. DOI: 10.1002/mds.30081.


Biomarkers for cognitive impairment in alpha-synucleinopathies: an overview of systematic reviews and meta-analyses.

Mantovani E, Martini A, Dinoto A, Zucchella C, Ferrari S, Mariotto S NPJ Parkinsons Dis. 2024; 10(1):211.

PMID: 39488513 PMC: 11531557. DOI: 10.1038/s41531-024-00823-x.


Complex Exercises Improve Cognition in People With Parkinson's Disease and Freezing of Gait.

Silva-Batista C, de Almeida F, Batista A, Barbosa E, Horak F, Ugrinowitsch C Neurorehabil Neural Repair. 2024; 39(1):3-15.

PMID: 39403970 PMC: 11723806. DOI: 10.1177/15459683241290793.


References
1.
Agosta F, Kostic V, Davidovic K, Kresojevic N, Sarro L, Svetel M . White matter abnormalities in Parkinson's disease patients with glucocerebrosidase gene mutations. Mov Disord. 2013; 28(6):772-8. DOI: 10.1002/mds.25397. View

2.
Tomlinson C, Stowe R, Patel S, Rick C, Gray R, Clarke C . Systematic review of levodopa dose equivalency reporting in Parkinson's disease. Mov Disord. 2010; 25(15):2649-53. DOI: 10.1002/mds.23429. View

3.
Hanganu A, Bedetti C, Degroot C, Mejia-Constain B, Lafontaine A, Soland V . Mild cognitive impairment is linked with faster rate of cortical thinning in patients with Parkinson's disease longitudinally. Brain. 2014; 137(Pt 4):1120-9. DOI: 10.1093/brain/awu036. View

4.
Hanganu A, Bedetti C, Jubault T, Gagnon J, Mejia-Constain B, Degroot C . Mild cognitive impairment in patients with Parkinson's disease is associated with increased cortical degeneration. Mov Disord. 2013; 28(10):1360-9. DOI: 10.1002/mds.25541. View

5.
Garcia-Diaz A, Segura B, Baggio H, Uribe C, Campabadal A, Abos A . Cortical thinning correlates of changes in visuospatial and visuoperceptual performance in Parkinson's disease: A 4-year follow-up. Parkinsonism Relat Disord. 2017; 46:62-68. DOI: 10.1016/j.parkreldis.2017.11.003. View